Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics

Journal of Correctional Health Care

Volumn 15, Issue 4, 2009, Pages 292-301

  Reeves, Rusty ^a   Kaldany, Herbert ^b   Lieberman, Jordan ^a   Vyas, Rajiv ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b New Jersey Department of Corrections   (United States)

Author keywords

Antipsychotics; Correctional health care; Medical record; Metabolic syndrome

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DRUG MONITORING; HUMAN; MEDICAL RECORD; METABOLIC SYNDROME X; PRISON;

ANTIPSYCHOTIC AGENTS; DRUG MONITORING; HUMANS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; METABOLIC SYNDROME X; PRISONS;

EID: 70350128438     PISSN: 10783458     EISSN: 19405200     Source Type: Journal    
DOI: 10.1177/1078345809340424     Document Type: Article

References (22)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65, 267-272.
2. Antai-Otong, D. (2004). Metabolic effects associated with atypical antipsychotic medications. Perspectives in Psychiatric Care, 40, 70-72.
3. Caro, J., Ward, A., Levinton, C., & Robinson, K. (2002). The risk of diabetes during olanzapine use compared with risperidone use: A retrospective database analysis. Journal of Clinical Psychiatry, 63, 1135-1139.
4. Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J.P., Citrome, L., McEvoy, J.,et al.(2002). Antipsychotic-induced weight gain and therapeutic response: A differential association. Journal of Clinical Psychopharmacology, 22, 244-251.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
6. Ford, E.S., Giles, W.H., & Dietz, W.H. (2002). Prevalence of the metabolic syndrome among U.S. adults: Findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association, 287, 356-359.
7. Haupt, D.W., Fahnestock, P.A., Flavin, K.A., Schweiger, J.A., Stevens, A., Hessler, M.J.,et al.(2007). Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology, 32, 2561-2569.
8. Holt, R.G., Peveler, R.C., & Byrne, C.D. (2004). Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine, 21, 515-523.
9. Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Lahti, K., Nissen, M.,et al.(2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683-689.
10. Johnson, A. (2008, February 28). Lilly faces initial Zyprexa trial. Wall Street Journal, p. D6.
11. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O.,et al.(2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
12. L'Italien, G.J., Casey, D.E., Kan, H.J., Carson, W.H., & Marcus, R.N. (2007). Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. Journal of Clinical Psychiatry, 68, 1510-1516.
13. McEvoy, J.P., Meyer, J.M., Goff, D.C., Nasrallah, H.A., Davis, S.M., Sullivan, L.,et al.(2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32.
14. Medical News Today. (2007, January 6). Genomas announces physiogenomic study that reveals potential cause of metabolic side effects in patients treated with psychotropic drugs. Retrieved October 15, 2007, from www.medicalnewstoday.com/articles/60201.php.
15. Meltzer, H.Y., & Bobo, W.V. (2006). Interpreting the efficacy findings in the CATIE study: What clinicians should know. CNS Spectrums, 11, 14-24.
16. Nasrallah, H. (2003). A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology, 28(Suppl. 1), 83-96.
17. Newcomer, J.W. (2007). Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. Journal of Clinical Psychiatry, 68(Suppl. 1), 20-27.
18. Osby, U., Correia, N., Brandt, L., Ekbom, A., & Sparen, P. (2000). Mortality and causes of death in schizophrenia in Stockholm County Sweden. Schizophrenia Research, 45, 21-28.
19. Petty, R. (2003). Diabetes in schizophrenia. Tucker, GA: Promedica Research Center.
20. Straker, D., Correll, C., Kramer-Ginsburg, E., Abdulhamid, N., Kosy, F., Rubens, E.,et al.(2005). Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. American Journal of Psychiatry, 162, 1217-1221.
21. Weiden, P.J., & McEvoy, J.P. (2005). Medical risk factors in patients with serious psychiatric disorders. Clinical Psychiatry News, Suppl. 3, 1-4.
22. World Health Organization. (1999). Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Retrieved October 15, 2007, from http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf.